Publicação
Efficacy of botulinum toxin type A in myogenic temporomandibulardisorders : a single arm, prospective, pilot study
| datacite.subject.fos | Ciências Médicas::Ciências da Saúde | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| dc.contributor.author | Sousa, Bruno Macedo de | |
| dc.contributor.author | López-Valverde, Nansi | |
| dc.contributor.author | Ferreira, Carolina | |
| dc.contributor.author | Almeida, André Mariz de | |
| dc.contributor.author | López-Valverde, Antonio | |
| dc.contributor.author | Rueda, José A. Blanco | |
| dc.date.accessioned | 2026-05-07T10:06:35Z | |
| dc.date.available | 2026-05-07T10:06:35Z | |
| dc.date.issued | 2025-12 | |
| dc.description.abstract | Background: Myogenous temporomandibular disorders (TMDs) is commonly associated with myofascial pain and functional limitations. Botulinum toxin type A (BoNT-A) has shown potential in relieving chronic muscular pain. Methods: In this single arm, prospective, pilot study, 25 patients diagnosed with myofascial TMDs received a single bilateral intramuscular injection of 50 units of BoNT-A. Assessments using the Visual Analog Scale (VAS), Chronic Pain Index (CPI), Jaw Functional Limitation Scale (JFLS-8), and Oral Health Impact Profile (OHIP-14) were performed at baseline, 6 weeks, and 12 weeks post-treatment. Results: Significant reductions in pain (VAS: 6.84 ± 1.03 to 0.84 ± 0.94) and CPI (61.87 ± 8.12 to 9.86 ± 4.46) were observed. Functional improvement (JFLS-8: 5.82 ± 0.56 to 1.08 ± 0.51) and enhanced quality of life (OHIP-14: 24.56 ± 8.39 to 5.96 ± 2.79) were also significant. No adverse effects were reported. Conclusions: BoNT-A showed promising results in reducing pain and improving function in patients with myofascial pain in Temporomandibular Disorders (M-TMDs). However, the single-arm design, small sample size, and short follow-up limit causal inference and external validity. These findings should be interpreted as preliminary. | eng |
| dc.identifier.citation | Macedo de Sousa B, López-Valverde N, Ferreira C, Almeida AM, López-Valverde A and Blanco Rueda JA (2025) Efficacy of botulinum toxin type A in myogenic temporomandibulardisorders: a single arm, prospective, pilot study. Front. Rehabil. Sci. 6:1737706. doi: 10.3389/fresc.2025.1737706 | |
| dc.identifier.doi | 10.3389/fresc.2025.1737706 | |
| dc.identifier.issn | 2673-6861 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/63017 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Frontiers Media | |
| dc.relation.hasversion | https://doi.org/10.3389/fresc.2025.1737706 | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | temporomandibular joint disorders | |
| dc.subject | myofascial pain | |
| dc.subject | botulinum toxin type A | |
| dc.subject | pain management | |
| dc.subject | quality of life | |
| dc.title | Efficacy of botulinum toxin type A in myogenic temporomandibulardisorders : a single arm, prospective, pilot study | eng |
| dc.type | contribution to journal | |
| dspace.entity.type | Publication | |
| oaire.citation.startPage | 1737706 | |
| oaire.citation.title | Frontiers in Rehabilitation Sciences | |
| oaire.citation.volume | 6 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |